Biontech Se 6-K Filing
Ticker: BNTX · Form: 6-K · Filed: Dec 3, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Dec 3, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Biontech Se (ticker: BNTX) to the SEC on Dec 3, 2025.
How long is this filing?
Biontech Se's 6-K filing is 1 pages with approximately 308 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 308 words · 1 min read · ~1 pages · Grade level 10.8 · Accepted 2025-12-03 16:30:18
Filing Documents
- d63919d6k.htm (6-K) — 12KB
- d63919dex991.htm (EX-99.1) — 24KB
- g63919g1203105940248.jpg (GRAPHIC) — 4KB
- 0001193125-25-306790.txt ( ) — 42KB
From the Filing
6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF DECEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-FForm 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On December 3, 2025, BioNTech SE (the "Company") issued a press release announcing the satisfaction of the minimum condition of its exchange offer for all outstanding shares of CureVac N.V. A copy of the press release is attached hereto as Exhibit 99.1. This report on Form 6-K shall be deemed to be filed and incorporated by reference in the Company's registration statement on Form F-4 (File No. 333-289468) and to be part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Prof. Dr. Ugur Sahin By: /s/ Dr. Sierk Poetting Name: Prof. Dr. Ugur Sahin Name: Dr. Sierk Poetting Title: Chief Executive Officer Title: Chief Operating Officer Date: December 3, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Achieves Minimum Condition in CureVac Exchange Offer